Hamid Emamekhoo

2.6k total citations · 1 hit paper
96 papers, 961 citations indexed

About

Hamid Emamekhoo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Hamid Emamekhoo has authored 96 papers receiving a total of 961 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 37 papers in Surgery. Recurrent topics in Hamid Emamekhoo's work include Bladder and Urothelial Cancer Treatments (37 papers), Renal cell carcinoma treatment (28 papers) and Cancer Immunotherapy and Biomarkers (26 papers). Hamid Emamekhoo is often cited by papers focused on Bladder and Urothelial Cancer Treatments (37 papers), Renal cell carcinoma treatment (28 papers) and Cancer Immunotherapy and Biomarkers (26 papers). Hamid Emamekhoo collaborates with scholars based in United States, Slovenia and United Kingdom. Hamid Emamekhoo's co-authors include Dieter C. Gruenert, Rosalie Maurisse, David de Semir, Alireza Abdolmohammadi, Christos E. Kyriakopoulos, Tian Zhang, Ana M. Molina, Matthew I. Milowsky, Ralph J. Hauke and Joshua M. Lang and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer.

In The Last Decade

Hamid Emamekhoo

87 papers receiving 947 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

2022 175 citations Hamid Emamekhoo, Ralph J. Hauke et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Hamid Emamekhoo

Since Specialization

Citations

This map shows the geographic impact of Hamid Emamekhoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hamid Emamekhoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hamid Emamekhoo more than expected).

Fields of papers citing papers by Hamid Emamekhoo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hamid Emamekhoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hamid Emamekhoo. The network helps show where Hamid Emamekhoo may publish in the future.

Co-authorship network of co-authors of Hamid Emamekhoo

This figure shows the co-authorship network connecting the top 25 collaborators of Hamid Emamekhoo. A scholar is included among the top collaborators of Hamid Emamekhoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hamid Emamekhoo. Hamid Emamekhoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	3077P Enfortumab vedotin with pembrolizumab (EVP) treatment outcomes in patients with histologic subtypes of advanced urothelial carcinoma: Analysis of the UNITE study	Annals of Oncology	C.-Y. Jiang, Omar Alhalabi et al.	0
2	1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)	Annals of Oncology	Joshua M. Lang, Susan F. Slovin et al.	1
3	A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.	Journal of Clinical Oncology	Evan Y. Yu, Luke T. Nordquist et al.	0
4	1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)	Annals of Oncology	Manish R. Patel, Jessica E. Hawley et al.	2
5	Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.	Journal of Clinical Oncology	Omar Alhalabi, Dimitra Rafailia Bakaloudi et al.	1
6	8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study	ESMO Open	Changying Jiang, Omar Alhalabi et al.	1
7	1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE	Annals of Oncology	Amanda Nizam, Li Zhang et al.	0
8	1989P Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis	Annals of Oncology	An‐Soo Jang, Chenyu Jiang et al.	0
9	Getting ready for real‐world use of electronic patient‐reported outcomes (ePROs) for patients with cancer: A National Comprehensive Cancer Network ePRO Workgroup paper	Cancer	Jennifer R. Cracchiolo, Ashish Atreja et al.	4
10	Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer	Journal for ImmunoTherapy of Cancer	Douglas G. McNeel, Hamid Emamekhoo et al.	29
11	Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.	Journal of Clinical Oncology	Amy K. Taylor, Jamie M. Sperger et al.	1
12	Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023	Journal for ImmunoTherapy of Cancer	Monika Joshi, Leonard Tuanquin et al.	18
13	Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti‐PD‐1 therapy	Pigment Cell & Melanoma Research	Yeonhee Park, Yusuf M. Mohamoud et al.	16
14	PARP inhibitors in metastatic prostate cancer	Frontiers in Oncology	Amy K. Taylor, David Kosoff et al.	36
15	1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)	Annals of Oncology	Jessica D. Lang, Scott T. Tagawa et al.	5
16	1415P Phase II trial of a DNA vaccine with nivolumab in patients with PSA-recurrent, castration-sensitive prostate cancer (nmCSPC)	Annals of Oncology	Douglas G. McNeel, Hamid Emamekhoo et al.	1
17	Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report	Anticancer Research	Hamid Emamekhoo, Timothy J. Ziemlewicz et al.	3
18	Percutaneous microwave ablation for local control of metastatic renal cell carcinoma	Abdominal Radiology	E. Jason Abel, Sara L. Best et al.	9
19	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma	Targeted Oncology	Alice Tzeng, C. Marcela Díaz‐Montero et al.	20
20	Sequence-Specific Correction of Genomic Hypoxanthine-Guanine Phosphoribosyl Transferase Mutations in Lymphoblasts by Small Fragment Homologous Replacement	Oligonucleotides	Lin Ye, Rosalie Maurisse et al.	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact